INTS INTS
Company Profile ↓Company Overview
INTS (INTS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -36.84% |
| 6 Months: | -53.33% |
| 3 Months: | -19.34% |
| 1 Month: | -12.13% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.93M | -1.77M | -1.25M | -1.22M | -2.49M | -4.74M | -5.07M | -3.57M | -3.39M | -2.71M | -2.73M | -2.53M |
| Net Income | -1.93M | -1.77M | -1.34M | -3.70M | -2.33M | -4.60M | -4.97M | -3.51M | -3.35M | -2.54M | -2.67M | -2.43M |
| Diluted EPS | -0.57 | -0.52 | -0.39 | -1.43 | -0.17 | -0.34 | -0.36 | -0.25 | -5.51 | -0.13 | -0.06 | -0.96 |
| R&D Expense | 1.39M | 1.16M | 774.00K | 859.00K | 1.35M | 2.81M | 3.56M | 2.15M | 2.19M | 1.54M | 1.55M | 1.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -7.55M | -8.32M | -16.59M | -11.97M |
| Net Income | -7.58M | -10.54M | -16.27M | -11.61M |
| Diluted EPS | -2.22 | -1.38 | -29.24 | -8.56 |
| R&D Expense | 5.13M | 4.79M | 10.50M | 6.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.76M | 17.30M | 4.78M | 14.10M |
| Total Equity | -8.69M | -15.10M | 13.16M | 2.92M | 11.88M |
| Cash & Equivalents | - | 1.31M | 8.56M | 2.59M | 11.92M |
| Total Liabilities | - | 6.86M | 4.13M | 1.86M | 2.23M |
| Current Liabilities | - | 6.82M | 3.96M | 1.75M | 2.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -5.48M | -7.21M | -15.22M | -9.23M |
| Investing Cash Flow | 0 | -6.02M | 6.35M | 0 |
| Financing Cash Flow | 2.25M | 20.47M | 2.90M | 18.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 50.2% | -80.1% | -557.5% | -97.7% |
| ROCE % | 149.2% | -62.4% | -547.7% | -100.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INTS
Intensity Therapeutics to Give Cancer Therapy Update Aug. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZHZQenhvclRuMFc0UmtseEc5M3BtZENmREdZUHlqZjAxWjI1cGNsUm1SeUg0WFlUc1NBWU42bkVReTNMSlJWV0EtYUpqclNxZ0VHUU1Fa1czM3NTVE1QbTVNV3diYnU2UFljZ1doSUF4aUhtSERsa1p5VWZzaC11S0RWYkdkUktOQkp6Um…
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNWFRzZU1BV2FpNlJ3ejBkOE1FT2tEbXB3WEhVLVVhWWpaSEFSYVozUHpTcWFyLXl6N25hNmVpMjhLWFBMcmtvcnBlM1VVcFBTOG1HdTZsY2R0ZThnOFpuQ01DcUhabWdfZDd1aUMzaE93SHpROG16RDR0Y2M4WWJVR3JBYXd0TmZHc3dyTX…
Intensity Therapeutics Announces Reverse Stock Split - PR Newswire
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPTDdTNDBoTm9MM0p0dWFxQ09HeXB3c3JiOW9wa2JKRXBsUUM0YkIwd18yV3ZsRHpHS0cyREN4UXFERDU0VElHR0Jid1NvbXJSc3o2ZHlVR1NNWTVWd3dYY3hDWmlfMkVVdFBPcnZhbEc0X2E4MndBNTdCNWFTSDNuaTZEMnBnM1JnbXJ2Vm…
INTS Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5EbzhVYzc0RW85ajZzWGRSb0dPa0ZYa293WTN1YS1vU3dwc0hGdS1OVm45SWRGWlhzZi1nSzcxZlEtRDV2SkpPaTVBTk1maG5jNURmUDZhMnIwOF9NSG1WZEl0TlZTTVkxcnQtcTFDQ2NJQ0ZrSV9Qam9B?oc=5" target="_blank">INT…
Why Did INTS Stock Plummet 25% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNjlGNWltUUNZSXdYOVctWGlYd1dHQWxoTVVnaDdPNTF1MDNFTXVDZWhHYXRRUjQxM3hUdnFGTVdSN0lhX2lvVzRxV1dYVWgwT0xBdEI0el9TYkVORmpNLVoxS09UcURYNDI1aVloUkZFX1E1b0VoS3Z0RXd4YmRzV3NhNEpJbjlrUVJhb2…
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOcHdvRlI5cFlUZmhQNEZNeXF4djhTeGdwNG9HNE9MMEpKVFZUZjQ2ZTZiUTI3dmNlVThRQXNqank0TUZ3VFhlUVJNdjZfcVR6Ym9ZZk5JMV96bS1qaERqa2o5dVdpTzU5RC1KV2ZEazBGaFhkakdER0E5RFc4OVBSR2lMMzBPbEVkdkJGdk…
INTS — Frequently Asked Questions
What is the current share price of INTS?
As of 2026-08-05 17:25 PDT, INTS trades at $4.20 on NASDAQ/NYSE. Its 52-week range is $3.62 to $33.00.
What is the P/E ratio of INTS?
INTS trades at a trailing price-to-earnings (P/E) ratio of -0.49.
What is the return on equity (ROE) of INTS?
INTS has a return on equity (ROE) of -97.73%. Its return on capital employed (ROCE) is -100.14%.
Is INTS a good stock to buy?
This page provides a data-driven analysis of INTS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.